Potential Benefits & Side Effects What early-phase clinical research describes
One case report
Temperature monitoring systems ensure storage parameters are within specified ranges
Comparative work with semaglutide (GLP-1R only) and tirzepatide (GIPR + GLP-1R) provides the field with a comprehensive map of how incremental receptor engagement reshapes downstream pharmacology across pancreatic, hepatic, adipose, and central nervous system tissues
After a 4-week screening period, participants were randomly assigned, 1:1:1:1:1, to once-weekly 2.5 mg, 5 mg, 10 mg or 15 mg VK2735 or placebo for 13 weeks
Pregnant or breastfeeding women: Individuals who are planning to become pregnant or are pregnant or breastfeeding should consult a healthcare professional before taking semaglutide, as its safety in these populations has not been established